Compare GAB & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAB | SRPT |
|---|---|---|
| Founded | 1986 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | N/A | 2000 |
| Metric | GAB | SRPT |
|---|---|---|
| Price | $5.22 | $17.66 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 24 |
| Target Price | N/A | ★ $21.73 |
| AVG Volume (30 Days) | 1.0M | ★ 2.5M |
| Earning Date | 01-01-0001 | 11-02-2026 |
| Dividend Yield | ★ 10.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.99 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.25 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $5.21 | $14.68 |
| 52 Week High | $6.37 | $25.32 |
| Indicator | GAB | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 31.14 | 40.85 |
| Support Level | N/A | $15.19 |
| Resistance Level | $5.72 | $18.16 |
| Average True Range (ATR) | 0.09 | 0.98 |
| MACD | -0.02 | -0.36 |
| Stochastic Oscillator | 3.77 | 10.73 |
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.